Rogers Corp (ROG)

85.53
NYSE : Technology
Prev Close 85.53
Day Low/High 0.00 / 0.00
52 Wk Low/High 51.98 / 90.45
Avg Volume 106.50K
Exchange NYSE
Shares Outstanding 18.09M
Market Cap 1.58B
EPS 2.70
P/E Ratio 32.93
Div & Yield N.A. (N.A)

Latest News

FDA Grants Breakthrough Therapy Designation For Rituxan® (Rituximab) In Pemphigus Vulgaris

FDA Grants Breakthrough Therapy Designation For Rituxan® (Rituximab) In Pemphigus Vulgaris

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Mylan Settles With Genentech Over Patents for Breast Cancer Drug

Mylan Settles With Genentech Over Patents for Breast Cancer Drug

The settlement provides Mylan with global licenses for its trastuzumab product.

Roche Diagnostics Recognizes Poplar Healthcare As Roche Molecular Center Of Excellence

Roche Diagnostics Recognizes Poplar Healthcare As Roche Molecular Center Of Excellence

Strategic alliance network is designed to help accelerate advancement of new methods in molecular diagnostics testing and personalized healthcare

Phase III APHINITY Study Shows Genentech's Perjeta® Regimen Helped People With An Aggressive Type Of Early Breast Cancer Live Longer Without Their Disease Returning Compared To Herceptin® And Chemotherapy

Phase III APHINITY Study Shows Genentech's Perjeta® Regimen Helped People With An Aggressive Type Of Early Breast Cancer Live Longer Without Their Disease Returning Compared To Herceptin® And Chemotherapy

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS) today announced positive results...

Rogers Corporation Reports Fourth Quarter 2016 And Full Year Results

Rogers Corporation Reports Fourth Quarter 2016 And Full Year Results

Rogers Corporation (NYSE:ROG) today announced financial results for the 2016 fourth quarter and full year.

Phase II Study Supports Potential For Genentech's Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) For People With Locally Advanced Or Metastatic Renal Cell Carcinoma

Phase II Study Supports Potential For Genentech's Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) For People With Locally Advanced Or Metastatic Renal Cell Carcinoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced encouraging results from the Phase II IMmotion150 study that compared TECENTRIQ ® (atezolizumab) plus Avastin ® (bevacizumab)...

Rogers Schedules Q4 & Full Year 2016 Earnings Call For Feb 21

Rogers Schedules Q4 & Full Year 2016 Earnings Call For Feb 21

Rogers Corporation (NYSE:ROG) plans to announce fourth quarter and full year 2016 results on February 20 after market close, which will be followed by a conference call on February 21 at 9 am ET.

News Out of Europe: Siemens Shares Hit Record High

News Out of Europe: Siemens Shares Hit Record High

Here is a round-up of the news from Europe.

FDA Grants Priority Review For Genentech's Actemra® (Tocilizumab) Supplemental Biologics License Application For Giant Cell Arteritis, A Form Of Vasculitis

FDA Grants Priority Review For Genentech's Actemra® (Tocilizumab) Supplemental Biologics License Application For Giant Cell Arteritis, A Form Of Vasculitis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Breakthrough Development For Americans With Suspected Heart Attack - Next Generation Troponin T Test From Roche Cleared By FDA

Breakthrough Development For Americans With Suspected Heart Attack - Next Generation Troponin T Test From Roche Cleared By FDA

New Troponin T 9-minute test offers greater sensitivity in the diagnosis of myocardial infarction

ROG Crosses Above Average Analyst Target

ROG Crosses Above Average Analyst Target

In recent trading, shares of Rogers Corp. have crossed above the average analyst 12-month target price of $78.67, changing hands for $80.66/share.

FDA Grants Genentech's Cancer Immunotherapy TECENTRIQ® (Atezolizumab) Priority Review In Additional Type Of Advanced Bladder Cancer

FDA Grants Genentech's Cancer Immunotherapy TECENTRIQ® (Atezolizumab) Priority Review In Additional Type Of Advanced Bladder Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Rogers Acquires Diversified Silicone Products, Inc.

Rogers Acquires Diversified Silicone Products, Inc.

Rogers Corporation (NYSE:ROG), a global leader in engineered material solutions, announced the acquisition of Diversified Silicone Products, Inc.

Rogers To Participate In The Needham Growth Conference

Rogers To Participate In The Needham Growth Conference

Rogers Corporation (NYSE:ROG) today announced Senior Vice President and CTO, Robert Daigle, and Vice President and CFO, Janice Stipp, will be presenting at the Nineteenth Annual Needham Growth Conference in New York...

Rogers To Participate In The CJS Securities New Ideas For The New Year Investor Conference

Rogers To Participate In The CJS Securities New Ideas For The New Year Investor Conference

Rogers Corporation (NYSE:ROG) today announced Senior Vice President and CTO, Robert Daigle, and Vice President and CFO, Janice Stipp, will be participating at the Seventeenth Annual CJS Securities "New Ideas for the...

Roche Gains FDA Clearance For 18-Minute Anti-Mullerian Hormone Test To Assess Ovarian Reserve

Roche Gains FDA Clearance For 18-Minute Anti-Mullerian Hormone Test To Assess Ovarian Reserve

New blood test measures the remaining egg supply of women who are planning to become pregnant

FDA Approves Genentech's Lucentis® (Ranibizumab Injection) For Myopic Choroidal Neovascularization

FDA Approves Genentech's Lucentis® (Ranibizumab Injection) For Myopic Choroidal Neovascularization

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Genentech's Emicizumab For Hemophilia A Meets Primary Endpoint In Phase III Study

Genentech's Emicizumab For Hemophilia A Meets Primary Endpoint In Phase III Study

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the primary endpoint has been met for the Phase III HAVEN 1 study evaluating emicizumab prophylaxis in people 12 years of age or...

Positive Phase III Results Of Genentech's Investigational Medicine OCREVUS™ (Ocrelizumab) Published In New England Journal Of Medicine

Positive Phase III Results Of Genentech's Investigational Medicine OCREVUS™ (Ocrelizumab) Published In New England Journal Of Medicine

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that data from three Phase III studies of its investigational medicine OCREVUS™ (ocrelizumab) - the OPERA I and OPERA II studies in...

FDA Extends Review Of Application For OCREVUS™ (Ocrelizumab)

FDA Extends Review Of Application For OCREVUS™ (Ocrelizumab)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.